28th Jun 2011 07:00
Notice of Annual General Meeting, Availability of 2010/11 Annual Report and Change to the Board of Directors
Chippenham, UK - 28 June 2011: Vectura Group plc (LSE: VEC) ("Vectura"), today gives notice of the following:
·; The Annual General Meeting (AGM) will be held on Friday, 22 July 2011 at the offices of Olswang LLP, 90 High Holborn, London WC1V 6XX, commencing at 11.00 am.
·; Copies of the Notice of Annual General Meeting and Form of Proxy and the Group's Annual Report and Accounts have been sent to shareholders today. These documents are available on the Investor Centre page of the Company's web site at www.vectura.com.
·; In accordance with Listing Rule 9.6.1, copies of the AGM documents have been submitted to the National Storage Mechanism and will be available for inspection shortly at www.hemscott.com/nsm.do.
·; After 11 years with Vectura, Dr Andrew Richards is not seeking re-election as a Non-Executive Director and will therefore resign from the Board at the end of the AGM.
Jack Cashman, Chairman of Vectura commented:
"Andy was appointed as a Non-Executive Director of Vectura in 2000, the year after the Company's formation, and we would like to thank him for his enormous contribution over the past 11 years."
-Ends -
Enquiries
Vectura Group plc | +44 (0)1249 667700 |
Chris Blackwell, Chief Executive | |
Anne Hyland, Chief Financial Officer | |
Julia Wilson, Director of Investor Relations |
Notes for editors
About Vectura
Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25 billion.
Vectura has six products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK).
Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.
For further information, please visit Vectura's website at www.vectura.com
Related Shares:
VEC.L